The MYG1 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian carcinoma cell line. This product provides a heterogeneous pool of cells carrying targeted disruption of the MYG1 gene, designed for studying loss-of-function effects in mitochondrial biology and ovarian cancer research. The polyclonal format eliminates the need for single-cell cloning and preserves population diversity, making it suitable for pooled functional screens or bulk biochemical assays where clonal artifacts are undesirable.
The A2780 cell line is a well-characterized model of epithelial ovarian cancer, established from an untreated endometrioid adenocarcinoma. With a near-diploid karyotype and retained cisplatin sensitivity, it is widely used to study drug resistance and metabolic adaptation. Its epithelial origin and stable genome provide a robust platform for probing mitochondrial gene disruptions in cancer.
MYG1 encodes a mitochondrial 3′-5′ exoribonuclease essential for RNA processing and ribosome assembly. It is regulated by NRF1 and PGC-1?? and modulated by mitochondrial stress signals. MYG1 interacts with large-subunit proteins MRPL2 and MRPL44, GTPBP10, and RNA granule components PNPase and GRSF1 to facilitate mitochondrial transcript maturation and incorporation of MRPLs and MRPSs. This activity directly governs mtDNA-encoded OXPHOS subunits MT-CO1 and MT-ND1, linking ribosome biogenesis to the oxidative phosphorylation system.
Disruption of MYG1 in these cisplatin-sensitive ovarian cancer cells provides a physiologically relevant system to dissect the contribution of mitochondrial translation and oxidative phosphorylation to cancer cell fitness and drug response. Ovarian cancer cells are known to undergo metabolic rewiring, and mitochondrial defects can modulate sensitivity to platinum-based chemotherapies. This polyclonal knockout pool enables direct comparison with wild-type A2780 cells, facilitating the study of mitochondrial-nuclear crosstalk and identification of metabolic vulnerabilities that may be exploited therapeutically.
The MYG1 polyclonal knockout cells are suitable for a broad range of functional assays. Researchers can assess OXPHOS complex expression by western blotting, measure de novo mitochondrial protein synthesis via pulse-chase labeling, and profile oxygen consumption using Seahorse respirometry. Additional applications include cell viability assays under cisplatin exposure, mtDNA copy number quantification by qPCR, immunofluorescence staining for mitochondrial markers, and RNA immunoprecipitation to detect MYG1-bound transcripts. For further technical information, please contact Ascent Research.
